Search

Your search keyword '"Kimber, Thomas"' showing total 48 results
Start Over Author "Kimber, Thomas" Publication Year Range Last 10 years
48 results on '"Kimber, Thomas"'

2. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Author

Aldred, Jason, Freire-Alvarez, Eric, Amelin, Alexander V., Antonini, Angelo, Bergmans, Bruno, Bergquist, Filip, Bouchard, Manon, Budur, Kumar, Carroll, Camille, Chaudhuri, K. Ray, Criswell, Susan R., Danielsen, Erik H., Gandor, Florin, Jia, Jia, Kimber, Thomas E., Mochizuki, Hideki, Robieson, Weining Z., Spiegel, Amy M., Standaert, David G., Talapala, Saritha, Facheris, Maurizio F., and Fung, Victor S. C.

Published
2023
Full Text
View/download PDF

3. An Interview with Dr. Kimber Thomas, Senior Innovation Specialist with the Connecting Communities Digital Initiative (CCDI) at the Library of Congress

Author

Tucker Taylor and Kimber Thomas

Subjects
Law, Law in general. Comparative and uniform law. Jurisprudence, K1-7720, Bibliography. Library science. Information resources
Abstract

In this interview, Dr. Thomas discusses the relationship between race and copyright. This conversation with Tucker Taylor of the Journal of Copyright in Education and Librarianship covers Dr. Thomas’s path to copyright education as well as her work at Connecting Communities Digital Initiative (CCDI) at the Library of Congress. Dr. Thomas details the interaction of race and copyright, and how it relates to librarianship and education. She also details ideas for librarians and educators to help improve our current situation.

Published
2024
Full Text
View/download PDF

4. Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Author

Aldred, Jason, Freire-Alvarez, Eric, Amelin, Alexander V., Antonini, Angelo, Bergmans, Bruno, Bergquist, Filip, Bouchard, Manon, Budur, Kumar, Carroll, Camille, Chaudhuri, K. Ray, Criswell, Susan R., Danielsen, Erik H., Gandor, Florin, Jia, Jia, Kimber, Thomas E., Mochizuki, Hideki, Robieson, Weining Z., Spiegel, Amy M., Standaert, David G., Talapala, Saritha, Facheris, Maurizio F., and Fung, Victor S. C.

Published
2023
Full Text
View/download PDF

5. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Author

Höglinger, Günter U, Litvan, Irene, Mendonca, Nuno, Wang, Deli, Zheng, Hui, Rendenbach-Mueller, Beatrice, Lon, Hoi-Kei, Jin, Ziyi, Fisseha, Nahome, Budur, Kumar, Gold, Michael, Ryman, Davis, Florian, Hana, Investigators, Arise, Ahmed, Anwar, Aiba, Ikuko, Albanese, Alberto, Bertram, Kelly, Bordelon, Yvette, Bower, James, Brosch, Jared, Claassen, Daniel, Colosimo, Carlo, Corvol, Jean-Christophe, Cudia, Paola, Daniele, Antonio, Defebvre, Luc, Driver-Dunckley, Erika, Duquette, Antoine, Eleopra, Roberto, Eusebio, Alexandre, Fung, Victor, Geldmacher, David, Golbe, Lawrence, Grandas, Francisco, Hall, Deborah, Hatano, Taku, Honig, Lawrence, Hui, Jennifer, Kerwin, Diana, Kikuchi, Akio, Kimber, Thomas, Kimura, Takashi, Kumar, Rajeev, Ljubenkov, Peter, Lorenzl, Stefan, Ludolph, Albert, Mari, Zoltan, McFarland, Nikolaus, Meissner, Wassilios, Rivera, Pablo Mir, Mochizuki, Hidek, Morgan, John, Munhoz, Renato, Nishikawa, Noriko, O`Sullivan, John, Oeda, Tomoko, Oizumi, Hideki, Onodera, Osamu, Ory-Magne, Fabienne, Peckham, Elizabeth, Postuma, Ronald, Quattrone, Aldo, Quinn, Joseph, Ruggieri, Stefano, Sarna, Justyna, Schulz, Paul E, Slevin, John, Tagliati, Michele, Wile, Daryl, Wszolek, Zbigniew, Xie, Tao, and Zesiewicz, Theresa

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Brain Disorders, Clinical Research, Clinical Trials and Supportive Activities, Patient Safety, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Neurological, Administration, Intravenous, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Female, Humans, Male, Middle Aged, Supranuclear Palsy, Progressive, Treatment Outcome, tau Proteins, Arise Investigators, Neurology & Neurosurgery, Clinical sciences
Abstract

BackgroundProgressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the safety and efficacy of tilavonemab for the treatment of progressive supranuclear palsy.MethodsWe did a phase 2, multicentre, randomised, placebo-controlled, double-blind study at 66 hospitals and clinics in Australia, Canada, France, Germany, Italy, Japan, Spain, and the USA. Participants (aged ≥40 years) diagnosed with possible or probable progressive supranuclear palsy who were symptomatic for less than 5 years, had a reliable study partner, and were able to walk five steps with minimal assistance, were randomly assigned (1:1:1) by interactive response technology to tilavonemab 2000 mg, tilavonemab 4000 mg, or matching placebo administered intravenously on days 1, 15, and 29, then every 28 days through to the end of the 52-week treatment period. Randomisation was done by the randomisation specialist of the study sponsor, who did not otherwise participate in the study. The sponsor, investigators, and participants were unaware of treatment allocations. The primary endpoint was the change from baseline to week 52 in the Progressive Supranuclear Palsy Rating Scale (PSPRS) total score in the intention-to-treat population. Adverse events were monitored in participants who received at least one dose of study drug. Prespecified interim futility criteria were based on a model-based effect size of 0 or lower when 60 participants had completed the 52-week treatment period and 0·12 or lower when 120 participants had completed the 52-week treatment period. This study is registered at ClinicalTrials.gov, number NCT02985879.FindingsBetween Dec 12, 2016, and Dec 31, 2018, 466 participants were screened, 378 were randomised. The study was terminated on July 3, 2019, after prespecified futility criteria were met at the second interim analysis. A total of 377 participants received at least one dose of study drug and were included in the efficacy and safety analyses (2000 mg, n=126; 4000 mg, n=125; placebo, n=126). Least squares mean change from baseline to week 52 in PSPRS was similar in all groups (between-group difference vs placebo: 2000 mg, 0·0 [95% CI -2·6 to 2·6], effect size 0·000, p>0·99; 4000 mg, 1·0 [-1·6 to 3·6], -0·105, p=0·46). Most participants reported at least one adverse event (2000 mg, 111 [88%]; 4000 mg, 111 [89%]; placebo, 108 [86%]). Fall was the most common adverse event (2000 mg, 42 [33%]; 4000 mg, 54 [43%]; placebo, 49 [39%]). Proportions of patients with serious adverse events were similar among groups (2000 mg, 29 [23%]; 4000 mg, 34 [27%]; placebo, 33 [26%]). Fall was the most common treatment-emergent serious adverse event (2000 mg, five [4%]; 4000 mg, six [5%]; placebo, six [5%]). 26 deaths occurred during the study (2000 mg, nine [7%]; 4000 mg, nine [7%]; placebo, eight [6%]) but none was drug related.InterpretationA similar safety profile was seen in all treatment groups. No beneficial treatment effects were recorded. Although this study did not provide evidence of efficacy in progressive supranuclear palsy, the findings provide potentially useful information for future investigations of passive immunisation using tau antibodies for progressive supranuclear palsy.FundingAbbVie Inc.

Published
2021

7. Improvement of “On” and “Off” Times in Patients with Advanced Parkinson’s Disease Treated with Foslevodopa/Foscarbidopa: Subgroup Analyses from a Phase 3 Randomized Study (S30.007)

Author

Kern, Drew, primary, Hauser, Robert, additional, Kimber, Thomas, additional, Vaou, Okeanis, additional, Bergmann, Lars, additional, Gupta, Resmi, additional, Jeong, Anna, additional, Jia, Jia, additional, Shah, Megha, additional, and Soileau, Michael, additional

Published
2024
Full Text
View/download PDF

8. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

Author

Soileau, Michael J, Aldred, Jason, Budur, Kumar, Fisseha, Nahome, Fung, Victor SC, Jeong, Anna, Kimber, Thomas E, Klos, Kevin, Litvan, Irene, O'Neill, Daniel, Robieson, Weining Z, Spindler, Meredith A, Standaert, David G, Talapala, Saritha, Vaou, Eleni Okeanis, Zheng, Hui, Facheris, Maurizio F, and Hauser, Robert A

Published
2022
Full Text
View/download PDF

9. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Author

Ahmed, Anwar, Aiba, Ikuko, Albanese, Alberto, Bertram, Kelly, Bordelon, Yvette, Bower, James, Brosch, Jared, Claassen, Daniel, Colosimo, Carlo, Corvol, Jean-Christophe, Cudia, Paola, Daniele, Antonio, Defebvre, Luc, Driver-Dunckley, Erika, Duquette, Antoine, Eleopra, Roberto, Eusebio, Alexandre, Fung, Victor, Geldmacher, David, Golbe, Lawrence, Grandas, Francisco, Hall, Deborah, Hatano, Taku, Höglinger, Günter U, Honig, Lawrence, Hui, Jennifer, Kerwin, Diana, Kikuchi, Akio, Kimber, Thomas, Kimura, Takashi, Kumar, Rajeev, Litvan, Irene, Ljubenkov, Peter, Lorenzl, Stefan, Ludolph, Albert, Mari, Zoltan, McFarland, Nikolaus, Meissner, Wassilios, Mir Rivera, Pablo, Mochizuki, Hidek, Morgan, John, Munhoz, Renato, Nishikawa, Noriko, O`Sullivan, John, Oeda, Tomoko, Oizumi, Hideki, Onodera, Osamu, Ory-Magne, Fabienne, Peckham, Elizabeth, Postuma, Ronald, Quattrone, Aldo, Quinn, Joseph, Ruggieri, Stefano, Sarna, Justyna, Schulz, Paul E, Slevin, John, Tagliati, Michele, Wile, Daryl, Wszolek, Zbigniew, Xie, Tao, Zesiewicz, Theresa, Mendonca, Nuno, Wang, Deli, Zheng, Hui, Rendenbach-Mueller, Beatrice, Lon, Hoi-Kei, Jin, Ziyi, Fisseha, Nahome, Budur, Kumar, Gold, Michael, Ryman, Davis, and Florian, Hana

Published
2021
Full Text
View/download PDF

11. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry

Author

Amalia, Ene, Arnold, Guy, Bajenaru, Ovidiu, Bergmans, Bruno, Bjornara, Kari Anne, Blackie, Jeff, Bode, Matthias, Bourgeois, Paul, Bohlhalter, Stephan, Buraga, Ioan, Burkhard, Pierre R., Busson, Philippe, Calopa, Matilde, Clausen, Jesper, Danielsen, Erik Hvid, Defebvre, Luc, Delvaux, Valerie, Dethy, Sophie, Dietrichs, Espen, De Fabregues, Oriol, Gerhard, Ransmayr, Gusmaroli, Graziano, Hahn, Kirsten, Hauptmann, Björn, Henriksen, Tove, Hernandez-Vara, Jorge, Jeanjean, A., Kaiserova, Michaela, Kassubek, Jan, Kimber, Thomas, Konitsiotis, Spyridon, Krüger, Rejko, Kulisevsky, Jaime, Leenders, Jo, Lundqvist, Christofer, Ory Magne, F., Marano, Pietro, Milanov, Ivan, Modugno, Nicola, Misbahuddin, Anjum, Nevrly, Martin, Panayiotis, Zikos, Pedersen, Kenn Freddy, Pedersen, Stephen W., Perju-Dumbrava, Lacramioara, Ponsen, M.M., Popescu, Bogdan O., Rijntjes, Michel, Puente, V., Redecker, Christoph, Schrader, Christoph, Sensi, Mariachiara, Simu, Mihaela, Spanaki, Cleanthe, Storch, Alexander, Storstein, Anette, Tomantschger, Volker, van der Linden, Chris, van Laar, T., Viallet, F., Witjas, Tatiana, Wolz, Martin, Zibetti, Maurizio, Van Zandijcke, Michel, Antonini, Angelo, Poewe, Werner, Chaudhuri, K. Ray, Jech, Robert, Pickut, Barbara, Pirtošek, Zvezdan, Szasz, Jozsef, Valldeoriola, Francesc, Winkler, Christian, Bergmann, Lars, Yegin, Ashley, Onuk, Koray, Barch, David, and Odin, Per

Published
2017
Full Text
View/download PDF

13. Characterizing a Parkinson’s Disease Population Inadequately Controlled by Oral Therapy: Baseline Characteristics of the Phase 3 Clinical Program for Foslevodopa/Foscarbidopa (P2-11.006)

Author

Odin, Per, primary, Pahwa, Rajesh, additional, Farmer, Jill, additional, Kimber, Thomas, additional, Bergmans, Bruno, additional, Alvarez, Eric Freire, additional, Chaudhuri, K Ray, additional, Gupta, Resmi, additional, Yan, Connie H., additional, Bergmann, Lars, additional, Kukreja, Pavnit, additional, and Antonini, Angelo, additional

Published
2023
Full Text
View/download PDF

14. Safety of Foslevodopa/Foscarbidopa During Optimization and Maintenance Treatment: Post Hoc Analysis of a Phase 3 Trial (S32.004)

Author

Kern, Drew, primary, Dashtipour, Khashayar, additional, Aldred, Jason, additional, Kimber, Thomas, additional, Iansek, Robert, additional, Kukreja, Pavnit, additional, Bergmann, Lars, additional, Fisseha, Nahome, additional, Gupta, Resmi, additional, Talapala, Saritha, additional, Jeong, Anna, additional, Fung, Victor, additional, and Lepetit, Vincent, additional

Published
2023
Full Text
View/download PDF

22. Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial

Author

Vivash, Lucy, primary, Bertram, Kelly L, additional, Malpas, Charles B, additional, Marotta, Cassandra, additional, Harding, Ian H, additional, Kolbe, Scott, additional, Fielding, Joanne, additional, Clough, Meaghan, additional, Lewis, Simon J G, additional, Tisch, Stephen, additional, Evans, Andrew H, additional, O’Sullivan, John D, additional, Kimber, Thomas, additional, Darby, David, additional, Churilov, Leonid, additional, Law, Meng, additional, Hovens, Christopher M, additional, Velakoulis, Dennis, additional, and O’Brien, Terence J, additional

Published
2021
Full Text
View/download PDF

23. Review: Against All Odds

Author

Kimber Thomas

Subjects
business.industry, Medicine, business, Demography, Odds
Published
2021

25. A Scoping Review of Psychological Assessment in Mission and Ministry Candidates

Author

Thompson, Katherine N., Kimber, Thomas, Williams, David, Matthews, Delle, Grossmann, Mathis, and Brautigam, Michael

Abstract

Missionary attrition together with the problem of institutional child sexual abuse in the Church has highlighted the importance of a standardized psychological assessment process for mission and ministry candidates. This scoping review aimed to examine peer-reviewed publications, from 2001 to 2021, which focused on the psychological assessment of ministry and cross-cultural mission candidates, to find knowledge gaps that exist. Using scoping review guidelines, 6,739 references were identified and 2,476 duplicates were removed. A further 4,254 references were excluded because they did not meet screening criteria. A total of nine high-quality articles remained, together with five articles that were added based on the bibliography of these references. This scoping review found the few papers published either focused on the use of personality tests or made recommendations about how these assessments should be conducted. The studies reported that candidates for ministry and mission in US samples have normative personality profiles regardless of age or ethnicity. Other papers reviewed knowledge and opinion and highlighted the need for screening for psychosexual development and to prevent attrition in mission and ministry roles. The overall dearth of publications suggested a need for more international research into how to standardize and utilize psychological assessments.

Published
2023
Full Text
View/download PDF

26. The Color Purple

Author

Kimber Thomas

Subjects
Cultural Studies, Arts and Humanities (miscellaneous)
Published
2021

30. Extending thrombolysis to 4·5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data

Author

Campbell, Bruce C V, primary, Ma, Henry, additional, Ringleb, Peter A, additional, Parsons, Mark W, additional, Churilov, Leonid, additional, Bendszus, Martin, additional, Levi, Christopher R, additional, Hsu, Chung, additional, Kleinig, Timothy J, additional, Fatar, Marc, additional, Leys, Didier, additional, Molina, Carlos, additional, Wijeratne, Tissa, additional, Curtze, Sami, additional, Dewey, Helen M, additional, Barber, P Alan, additional, Butcher, Kenneth S, additional, De Silva, Deidre A, additional, Bladin, Christopher F, additional, Yassi, Nawaf, additional, Pfaff, Johannes A R, additional, Sharma, Gagan, additional, Bivard, Andrew, additional, Desmond, Patricia M, additional, Schwab, Stefan, additional, Schellinger, Peter D, additional, Yan, Bernard, additional, Mitchell, Peter J, additional, Serena, Joaquín, additional, Toni, Danilo, additional, Thijs, Vincent, additional, Hacke, Werner, additional, Davis, Stephen M, additional, Donnan, Geoffrey A, additional, Donnan, Geoffrey A., additional, Davis, Stephen M., additional, Campbell, Bruce C.V., additional, Parsons, Mark W., additional, Mitchell, Peter J., additional, Desmond, Patricia M., additional, Oxley, Thomas, additional, Wu, Teddy Y., additional, Shah, Darshan, additional, Zhao, Henry, additional, Rodrigues, Edrich, additional, Salvaris, Patrick, additional, Alemseged, Fana, additional, Ng, Felix, additional, Williams, Cameron, additional, Ng, Jo-Lyn, additional, Tu, Hans T-H., additional, McDonald, Amy, additional, Jackson, David, additional, Tsoleridis, Jessica, additional, McCoy, Rachael, additional, Pesavento, Lauren, additional, Weir, Louise, additional, Kleinig, Timothy J., additional, Patel, S., additional, Harvey, J., additional, Mahadevan, J., additional, Cheong, E., additional, Balabanski, Anna, additional, Waters, Michael, additional, Drew, Roy, additional, Cranefield, Jennifer, additional, Mackey, Elizabeth, additional, Celestino, Sherisse, additional, Low, Essie, additional, Dewey, Helen M., additional, Bladin, Christopher F., additional, Loh, Poh Sien, additional, Choi, Philip M., additional, Coote, Skye, additional, Frost, Tanya, additional, Hogan, K., additional, Ding, C., additional, McModie, S., additional, Zhang, W.W., additional, Kyndt, Christopher, additional, Moore, A., additional, Ross, Z., additional, Liu, J., additional, Miteff, Ferdinand, additional, Levi, Christopher R., additional, Ang, Timothy, additional, Spratt, Neil, additional, Garcia-Esperon, Carlos, additional, Kaauwai, Lara, additional, Phan, Thanh G., additional, Ly, John, additional, Singhal, Shaloo, additional, Clissold, Benjamin, additional, Wong, Kitty, additional, Krause, Martin, additional, Day, Susan, additional, Sturm, Jonathan, additional, O'Brian, Bill, additional, Grimley, Rohan, additional, Simpson, Marion, additional, Lee-Archer, Matthew, additional, Brodtmann, Amy, additional, Coulton, Bronwyn, additional, Young, Dennis, additional, Wong, Andrew A., additional, Muller, Claire, additional, Field, Deborah K., additional, Vallat, W., additional, Maxwell, Vanessa, additional, Bailey, Peter, additional, Sabet, Arman, additional, Mishra, Sachin, additional, Tan, Meng, additional, George, K., additional, Barber, P. Alan, additional, Zhao, L., additional, Meretoja, Atte, additional, Tatlisumak, Turgut, additional, Sibolt, G., additional, Tiainen, M., additional, Koivu, M., additional, Aarnio, K., additional, Virta, J., additional, Kasari, O., additional, Eirola, S., additional, Sun, M.C., additional, Chen, T.C., additional, Chuang, C.S., additional, Chen, Y.Y., additional, Lin, C.M., additional, Ho, S.C., additional, Hsiao, P.M., additional, Tsai, C.H., additional, Huang, W.S., additional, Yang, Y.W., additional, Huang, H.Y., additional, Wang, W.C., additional, Liu, C.H., additional, Lu, M.K., additional, Lu, C.H., additional, Kung, W.L., additional, Jiang, S.K., additional, Wu, Y.H., additional, Huang, S.C., additional, Tseng, C.H., additional, Tseng, L.T., additional, Guo, Y.C., additional, Lin, D., additional, Hsu, C.T., additional, Kuan, C.W., additional, Hsu, J.P., additional, Tsai, H.T., additional, Suzuki, M., additional, Sun, Y., additional, Chen, H.F., additional, Lu, C.J., additional, Lin, C.H., additional, Huang, C.C., additional, Chu, H.J., additional, Lee, C.Y., additional, Chang, W.H., additional, Lo, Y.C., additional, Hsu, Y.T., additional, Chen, C.H., additional, Sung, P.S., additional, Ysai, C.L., additional, Jeng, J.S., additional, Tang, S.C., additional, Tsai, L.K., additional, Yeh, S.J., additional, Lee, Y.C., additional, Wang, Y.T., additional, Chung, T.C., additional, Hu, C.J., additional, Chan, L., additional, Chiou, Y.W., additional, Lien, L.M., additional, Yeh, H.L., additional, Yeh, J.H., additional, Chen, W.H., additional, Lau, C.L., additional, Chang, A., additional, Lee, I.Y., additional, Huang, M.Y., additional, Lee, J.T., additional, Peng, G.S., additional, Lim, J.C., additional, Hsu, Y.D., additional, Lin, C.C., additional, Cheng, C.A., additional, Yen, C.H., additional, Yang, F.C., additional, Hsu, C.H., additional, Sung, Y.F., additional, Tsai, C.K., additional, Tsai, C.L., additional, Lee, A., additional, Hankey, Graeme, additional, Blacker, David, additional, Gerraty, Richard, additional, Chen, C-I., additional, Hsu, C-S., additional, Cowley, Elise, additional, Sallaberger, Michele, additional, Snow, Barry, additional, Kolbe, John, additional, Stark, Richard, additional, King, John, additional, Macdonnell, Richard, additional, Attia, John, additional, D'Este, Catherine, additional, Bernhardt, Julie, additional, Carey, Leeanne, additional, Cadilhac, Dominique, additional, Anderson, Craig, additional, Howells, David, additional, Barber, A., additional, Connelly, Alan, additional, Macleod, Malcolm, additional, O'Collins, Victoria, additional, Wilson, W., additional, Macaulay, L., additional, Bluhmki, Erich, additional, Eschenfelder, Christoph, additional, Ringleb, Peter, additional, Schellinger, Peter, additional, Wahlgren, Nils, additional, Wardlaw, Joanna, additional, Oppenheim, Catherine, additional, Lees, Kennedy R., additional, Kaste, Markku, additional, von Kummer, Rüdiger, additional, Chatellier, Gilles, additional, Laage, Rico, additional, Nuñez, Xavier, additional, Ehrenkrona, Christina, additional, Svenson, Ann-Sofie, additional, Cove, Lynda, additional, Niederkorn, Kurt, additional, Gruber, Franz, additional, Kapeller, Peter, additional, Mikulik, Robert, additional, Mas, Jean-Louis, additional, Berrouschot, Jörg, additional, Sobesky, Jan, additional, Köhrmann, Martin, additional, Steiner, Thorsten, additional, Kessler, Christof, additional, Dziewas, Rainer, additional, Poli, Sven, additional, Althaus-Knaurer, Katharina, additional, Bovi, Paolo, additional, Rodriguez, Alain L., additional, Arenillas, Juan F., additional, Muir, Keith, additional, Veltkamp, Roland, additional, Dixit, Anand, additional, Muddegowda, Girish, additional, Kala, Lalit, additional, De Silva, Deidre A., additional, Butcher, Kenneth S., additional, Byrnes, G., additional, Peeters, Andre, additional, Chalk, J.B., additional, Fink, John N., additional, Kimber, Thomas E., additional, Schultz, David, additional, Hand, Peter J., additional, Frayne, Judith, additional, Tress, Brian M., additional, McNeil, John, additional, Burns, R., additional, Johnston, C., additional, and Williams, M., additional

Published
2019
Full Text
View/download PDF

33. A blinded, controlled trial of objective measurement in Parkinson's disease.

Author

Woodrow, Holly, Horne, Malcolm K., Fernando, Chathurini V., Kotschet, Katya E., Treat to Target Study Group, Bhattacharya, Arup, Blaze, Richard, Charmley, Andrew, Cruse, Belinda, Duma, Stephen, Evans, Andrew, Ghaly, Mina, Giarola, Blake, Halliday, Amy J., Kimber, Thomas, Kumar, Anand, Lehn, Alexander, Lilley, Kate, Ma, Andrew, and Mahant, Neil

Published
2020
Full Text
View/download PDF

35. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry

Author

Antonini, Angelo, primary, Poewe, Werner, additional, Chaudhuri, K. Ray, additional, Jech, Robert, additional, Pickut, Barbara, additional, Pirtošek, Zvezdan, additional, Szasz, Jozsef, additional, Valldeoriola, Francesc, additional, Winkler, Christian, additional, Bergmann, Lars, additional, Yegin, Ashley, additional, Onuk, Koray, additional, Barch, David, additional, Odin, Per, additional, Amalia, Ene, additional, Arnold, Guy, additional, Bajenaru, Ovidiu, additional, Bergmans, Bruno, additional, Bjornara, Kari Anne, additional, Blackie, Jeff, additional, Bode, Matthias, additional, Bourgeois, Paul, additional, Bohlhalter, Stephan, additional, Buraga, Ioan, additional, Burkhard, Pierre R., additional, Busson, Philippe, additional, Calopa, Matilde, additional, Clausen, Jesper, additional, Danielsen, Erik Hvid, additional, Defebvre, Luc, additional, Delvaux, Valerie, additional, Dethy, Sophie, additional, Dietrichs, Espen, additional, De Fabregues, Oriol, additional, Gerhard, Ransmayr, additional, Gusmaroli, Graziano, additional, Hahn, Kirsten, additional, Hauptmann, Björn, additional, Henriksen, Tove, additional, Hernandez-Vara, Jorge, additional, Jeanjean, A., additional, Kaiserova, Michaela, additional, Kassubek, Jan, additional, Kimber, Thomas, additional, Konitsiotis, Spyridon, additional, Krüger, Rejko, additional, Kulisevsky, Jaime, additional, Leenders, Jo, additional, Lundqvist, Christofer, additional, Ory Magne, F., additional, Marano, Pietro, additional, Milanov, Ivan, additional, Modugno, Nicola, additional, Misbahuddin, Anjum, additional, Nevrly, Martin, additional, Panayiotis, Zikos, additional, Pedersen, Kenn Freddy, additional, Pedersen, Stephen W., additional, Perju-Dumbrava, Lacramioara, additional, Ponsen, M.M., additional, Popescu, Bogdan O., additional, Rijntjes, Michel, additional, Puente, V., additional, Redecker, Christoph, additional, Schrader, Christoph, additional, Sensi, Mariachiara, additional, Simu, Mihaela, additional, Spanaki, Cleanthe, additional, Storch, Alexander, additional, Storstein, Anette, additional, Tomantschger, Volker, additional, van der Linden, Chris, additional, van Laar, T., additional, Viallet, F., additional, Witjas, Tatiana, additional, Wolz, Martin, additional, Zibetti, Maurizio, additional, and Van Zandijcke, Michel, additional

Published
2017
Full Text
View/download PDF

45. Dystonia-Parkinsonism Due to Pallidal and Nigral Necrosis Following Heroin Overdose: Long-Term Evolution.

Author

Shu, Siew Lee, Thompson, Philip D., and Kimber, Thomas E.

Subjects
DYSTONIA, MUSCLE diseases, MOVEMENT disorders, EXTRAPYRAMIDAL disorders, HEROIN abuse, HEROIN
Abstract

The article examines the case of a patient with dystonia-parkinsonism due to pallidal and nigral necrosis following heroin overdose. The patient has a history of marijuana use, post-traumatic stress disorder, depression and amphetamine-induced psychosis. Examination of the patient revealed right hemichorea and impairment of left-sided fractioned finger movements. It revealed that the evolution from hemichorea to dystonia was owing to acute and subacute effect of pallidal anoxia, respectively.

Published
2016
Full Text
View/download PDF

46. Fashion victim: rhabdomyolysis and bilateral peroneal and tibial neuropathies as a result of squatting in 'skinny jeans'.

Author

Wai, Karmen, Thompson, Philip Douglas, and Kimber, Thomas Edmund

Subjects
MUSCLE weakness, NEURAL conduction, JEANS (Clothing), PERIPHERAL neuropathy diagnosis, CLOTHING & dress, ENTRAPMENT neuropathies, PERIPHERAL neuropathy, POSTURE, RHABDOMYOLYSIS, DISEASE complications
Abstract

The article discusses the case of a female patient diagnosed with rhabdomyolysis and bilateral peroneal and tibial neuropathies caused by wearing and squatting in tight jeans. Topics discussed include the clinical presentation of the patient which include severe weakness of both ankles and impaired sensation, results of nerve conduction studies and the treatment of the patient intravenous hydration.

Published
2016
Full Text
View/download PDF

47. Electroconvulsive therapy for the neurological and psychiatric manifestations of multiple system atrophy.

Author

Chia, Nicholas, Kimber, Thomas, and Ash, David

Subjects
*PREVENTION of mental depression, *TREATMENT of neurodegeneration, *ELECTROCONVULSIVE therapy, *HEALTH outcome assessment, *ACTIVITIES of daily living, *TREATMENT effectiveness
Abstract

A letter to the editor is presented regarding a 64 year old businesswoman presented with treatment-resistant depression and multiple system atrophy (MSA) wherein electroconvulsive therapy (ECT) 3 times per week improved her physical symptoms.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results